The National Health Insurance Administration (NHIA) said it plans to expand the coverage eligibility for receiving a third-generation targeted drug for lung cancer patients with the epidermal growth factor receptor (EGFR) starting next month.
The eligibility would be expanded to include people with stage 3b EGFR-mutated lung cancer, which is expected to benefit about 4,000 people, allowing them to save about NT$1.15 million (US$36,005) per year in medical expenses.
The expanded eligibility is expected to cost the NHI program between NT$4.1 billion and NT$5 billion per year, and with the annual expense of about NT$3.3 billion on eligible patients, the targeted drug would be the most expensive single type of drug in NHI history.
Photo: Chiu Chih-jou, Taipei Times
Lung adenocarcinoma is the most common type of lung cancer in Taiwan and KRAS mutations occur in about 20 to 40 percent of lung adenocarcinomas in Western populations, NHIA Director-General Shih Chung-liang (石崇良) said.
However, in Taiwan, KRAS mutations only occur in about 8 to 10 percent of patients with lung adenocarcinomas, while EGFR mutations occur in about 55 to 60 percent of patients with lung adenocarcinomas, he said.
The NHI program since April 2020 has conditionally covered a third-generation targeted drug called Tagrisso (osimertinib) for the treatment of EGFR-mutated lung cancer, but the eligibility was reduced in April 2022, which had caused an uproar among patients and medical professionals.
Studies published in international journals have suggested that compared with the first-generation targeted drug, the third-generation drug can reduce the risk of mortality by 20 percent.
With many calls for the NHI program to expand eligibility, Shih said the administration plans to expand the eligibility of Tagrisso from its current eligibility of stage 4 (metastasized) lung cancer to include stage 3b EGFR-mutated lung cancer with local invasiveness or metastases.
The Pharmaceutical Benefit and Reimbursement Scheme Joint Committee has approved the expanded eligibility, and it is scheduled to take effect on Oct. 1 at the earliest, he said.
About 3,400 people are treated with Tagrisso each year, which is an NHI expenditure of about NT$3.3 billion per year, NHIA statistics showed. After the eligibility expansion, it would increase the expenditure to more than NT$7 billion.
The total expenditure for NHI-covered medical treatment last year was more than NT$24.3 billion, the highest among all cancer types, and drug fees accounted for NT$12.2 billion, with a five-year average growth rate of 12.7 percent.
Regarding people with lung cancer without gene mutations that cannot receive the targeted drug, Shih said specialists have suggested including immunotherapy drugs for treating metastasized small cell lung cancer in NHI coverage, so there might be good news after the agency negotiates with drug companies.
An estimated 272 to 359 patients each year are expected to benefit from it, allowing them to save about NT$1.45 million per person per year, he added.
Considering that most countries issue more than five denominations of banknotes, the central bank has decided to redesign all five denominations, the bank said as it prepares for the first major overhaul of the banknotes in more than 24 years. Central bank Governor Yang Chin-lung (楊金龍) is expected to report to the Legislative Yuan today on the bank’s operations and the redesign’s progress. The bank in a report sent to the legislature ahead of today’s meeting said it had commissioned a survey on the public’s preferences. Survey results showed that NT$100 and NT$1,000 banknotes are the most commonly used, while NT$200 and NT$2,000
The Centers for Disease Control (CDC) yesterday reported the first case of a new COVID-19 subvariant — BA.3.2 — in a 10-year-old Singaporean girl who had a fever upon arrival in Taiwan and tested positive for the disease. The girl left Taiwan on March 20 and the case did not have a direct impact on the local community, it said. The WHO added the BA.3.2 strain to its list of Variants Under Monitoring in December last year, but this was the first imported case of the COVID-19 variant in Taiwan, CDC Deputy Director-General Lin Ming-cheng (林明誠) said. The girl arrived in Taiwan on
South Korea is planning to revise its controversial electronic arrival card, a step Taiwanese officials said prompted them to hold off on planned retaliatory measures, a South Korean media report said yesterday. A Yonhap News Agency report said that the South Korean Ministry of Foreign Affairs is planning to remove the “previous departure place” and “next destination” fields from its e-arrival card system. The plan, reached after interagency consultations, is under review and aims to simplify entry procedures and align the electronic form with the paper version, a South Korean ministry official said. The fields — which appeared only on the electronic form
The Ministry of Foreign Affairs (MOFA) is suspending retaliation measures against South Korea that were set to take effect tomorrow, after Seoul said it is updating its e-arrival system, MOFA said today. The measures were to be a new round of retaliation after Taiwan on March 1 changed South Korea's designation on government-issued alien resident certificates held by South Korean nationals to "South Korea” from the "Republic of Korea," the country’s official name. The move came after months of protests to Seoul over its listing of Taiwan as "China (Taiwan)" in dropdown menus on its new online immigration entry system. MOFA last week
RSS